FOXD2 and bladder transitional cell carcinoma: Notably, ASO-mediated knockdown of LINC01094 enhanced BLCA cell sensitivity to cisplatin and gemcitabine, paralleling earlier findings that other lncRNAs (e.g., FOXD2-AS1 and DLEU1) modulate chemoresistance via EMT-related mechanisms (34–37).